Evolence

Generic name: dermal filler
Company: Ortho Neutrogena
Approval date: June 27, 2008

Medically reviewed by Drugs.com. Last updated on Jun 1, 2022.

Note: Withdrawn from U.S. market on November 2009.

What is the most important information I should know about Evolence?

Evolence was withdrawn from the U.S. market in November of 2009.

The U.S. Food and Drug Administration approved Evolence, a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds, in June of 2008.

Patients with known hypersensitivity to any collagen products or planning to undergo desensitization injections to porcine products should not use Evolence, as these injections can contain porcine collagen.

Evolence is injected into the mid-to-deep dermis. The most common side effects of Evolence injections are usually injection-site related and include mild swelling, redness, and pain. Other rare side effects include the development of small areas of firmness under the skin at the treated sites that may be noticed when the areas are pressed upon.

What is Evolence?

Evolence was withdrawn from the U.S. market in November of 2009.

Evolence collagen filler is a porcine collagen gel implant composed of 3.5% (35 mg/mL) homogenous Type I collagen that was extracted and purified from porcine tendons and suspended in phosphate-buffered saline (PBS) and which has been cross-linked with ribose-mediated technology. Evolence collagen is cross-linked through its patented Glymatrix Technology using the natural sugar, D-Ribose.

Evolence is supplied as a single-use, prefilled syringe.

Contraindictions:

Evolence was withdrawn from the U.S. market in November of 2009.

Evolence Collagen Filler is contraindicated in the following:

• Patients with known hypersensitivity to any collagen products or planning to undergo desensitization injections to porcine products, as these injections can contain porcine collagen.

• Patients with a history of anaphylactic reactions or history or presence of severe recurrent allergic reactions.

• Evolence Collagen Filler should not be implanted in spaces other than the dermis of the face.

• Evolence Collagen Filler should not be implanted in patients with bleeding disorders.

Warnings

Evolence was withdrawn from the U.S. market in November of 2009.

• Local necrosis is a rare event, which has been observed following other collagen implantation and may occur following injections to the glabella. It is thought to result from the injury, obstruction, or compromise of blood vessels.
• Patients with a history of dietary porcine allergy should be carefully examined before porcine collagen injections, since it is possible that the collagen component of the porcine material may be causing the allergy.
• Avoid injecting Evolence into blood vessels as collagen can initiate platelet aggregation and may cause vascular occlusion and localized infarction or embolic phenomena.
• Use of Evolence at specific sites in which infections or active inflammatory reaction is present, sh...